Oct 1, 2023
How can patients help shape the future of scientific innovation?
What's the vital role of the patient's voice in developing
life-changing medicines? In this captivating episode, fresh off her
thought-provoking appearance at the 9th Annual BioHealth Capital
Region Forum, Dr. Theresa Podrebarac takes us on a journey through
the dynamic landscape of autoimmune medicine.
Dr. Podrebarac is a renowned physician scientist with a wealth of
expertise in the biotech industry. As the Senior Vice President of
Clinical Development at Horizon Therapeutics, she's at the
forefront of bringing hope to patients with rare, autoimmune, and
severe inflammatory diseases. Join us as we explore pivotal
questions:
- What is Horizon Therapeutics' mission, and what are Dr. Podrebarac's primary responsibilities in this quest for life-changing medicines?
- How has Dr. Podrebarac's background as a rheumatologist influenced her belief in the importance of the patient's perspective in drug development?
- Discover Horizon's impressive journey in clinical development, with a sharp focus on autoimmune diseases.
- Dive into Horizon's global presence and the crucial role of its Maryland operations.
- What are the clinical goals that will shape the future of autoimmune medicine?
Don't miss this enlightening conversation that delves into the
nexus of science, patient advocacy, and innovation. Tune in now and
become part of the future where patients' voices are not just heard
but lead the way in shaping a brighter tomorrow. Available on all
major podcasting platforms.
Theresa Podrebarac, M.D., M.Sc., is a physician scientist with
extensive development expertise in the biotech industry. At Horizon
Therapeutics, Dr. Podrebarac leads the clinical development
function dedicated to bringing medicines for rare, autoimmune and
severe inflammatory diseases to patients. Prior to Horizon, Dr.
Podrebarac served as chief medical officer at two biotech companies
focusing on rare diseases. She was also vice president,
immunology clinical development at AbbVie where she helped develop
approved therapies for psoriasis and rheumatoid arthritis. At
Biogen, she championed the development of tools and techniques for
early clinical proof of concept in diseases including scleroderma
and lupus skin disease.
Dr. Podrebarac holds a master of science in immunology from the
University of Ottawa and a medical doctorate degree from Western
University. She completed a postdoctoral fellowship in immunology
at Harvard University.